Exscientia to start world-first trials of AI-designed immuno-oncology drug
Oxford-based AI drug discovery firm Exscientia is preparing to begin Phase I clinical trials with the world’s first AI-designed molecule for immuno-oncology.
Latest News
View More
ObvioHealth Q&A: connecting DCT dots with remote tech
The move towards decentralised clinical trials has been accelerated by Covid-19, and the tech that underpins remote trials is evolving…
Latest News
View More
ImmunityBio’s Covid-19 vaccine induces robust T cell response in trial
ImmunityBio has reported initial data from Phase I clinical trial of its hAd5 Covid-19 vaccine candidate which stimulated the generation of T cell reactive to…
GHO Capital to acquire Velocity Clinical Research from NaviMed
Global Healthcare Opportunities (GHO Capital) has signed an agreement to acquire US integrated clinical trial site organisation Velocity Clinical Research from NaviMed Capital and other…
Exscientia to start world-first trials of AI-designed immuno-oncology drug
Oxford-based AI drug discovery firm Exscientia is preparing to begin Phase I clinical trials with the world’s first AI-designed molecule…
Claritas to expand Covid-19 trial to include sepsis treatment
Claritas Pharmaceuticals is set to expand its development programme for R-107 to include the treatment of Covid-19 related sepsis, which…
Laurent to continue study of LAU-7b in Covid-19 patients
Laurent Pharmaceuticals has decided to continue the study of its pro-resolving drug LAU-7b without modification in the Phase II RESOLUTION…
BlueRock Therapeutics to start cell therapy trial for Parkinson’s disease
BlueRock Therapeutics is all set to initiate Phase I Study of MSK-DA01 Cell Therapy for advanced Parkinson’s disease (PD) after…
Expert Commentary & Analysis
View MoreLoA Update: Amryt’s Juxtapid sees 7-point surge in US approval prospects in familial chylomicronaemia due to positive investigator-led Phase III trial
Amryt Pharma’s Juxtapid (lomitapide) had a 7-point jump in its Likelihood of Approval (LoA) in familial chylomicronaemia syndrome (FCS) on the heels of positive data from an investigator-led Phase III…
J&J’s double-dose Covid-19 vaccine draws differing expert reviews on US rollout with single-dose version already authorised
Johnson & Johnson’s Phase III double-dose Covid-19 vaccine prompted a range of expert analyses as to how the prime-boost regimen would be rolled out considering the single-dose approach is already…
LoA Update: AMO Pharma’s AMO-1 for PMS and epilepsy sees 13-point leap in regulatory potential following investigator-sponsored Phase II completion
The likelihood of approval (LoA) for AMO Pharma’s AMO-01 in Phelan-McDermid Syndrome (PMS) with co-morbid epilepsy jumped 13 points as of 29 March, according to GlobalData’s LoA data. The score change was…
Latest Themes
View More
THREAD Q&A: bridging the gap between patients and trials with social media
THREAD, a tech-focused service provider that enables decentralised clinical trials, has recently penned a partnership with CureClick, a community-powered platform...
Akili presents more positive trial data for ADHD gaming therapy
Akili Interactive has published data from its STARS-Adjunct trial supporting the efficacy of EndeavorRx, its attention-deficit hyperactivity disorder (ADHD) video game therapy for kids, in...
MHRA pilot aims to boost patient involvement in clinical research
In a bid to put patient involvement at the heart of drug development and clinical trials, the Medicines and Healthcare products Regulatory Agency (MHRA) has...
ObvioHealth Q&A: connecting DCT dots with remote tech
The move towards decentralised clinical trials has been accelerated by Covid-19, and the tech that underpins remote trials is evolving at a matching pace. Clinical...
Company Whitepapers
View MoreCompany A-Z
View More
VaLea Clinical Trials
Patient-Centric Services for In-Home or Alternate-Site Clinical Trials Settings
Sustained interest in oncology radiopharmaceuticals expected after positive results from 177Lu-PSMA-617 in prostate cancer
Radiopharmaceuticals play a niche role in treating cancer, despite having labels in multiple oncology indications in the US and EU, with few agents being commercially successful. In March, Novartis announced…